arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CANNAPHARMARX, INC.

CPMD
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
63 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Neutral
auto_awesome

Analytical Summary

CANNAPHARMARX, INC. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth 19.3% ↘
Op. Margin -137.1% ↘
ROIC 1.2% ↘
FCF / Share $-0.00
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$276.22K
↑ +19.3% —
Net Income Profit after all expenses
$-1.91M
↓ -35.1% —
Operating Margin Operating profit as % of sales
-137.1%
↓ -26.1% 0th
FCF / Share Free cash flow per share
$-0.00
↑ +72.3% —
Long-Term Debt Long-term obligations
$7.00M
↓ -0.5% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns ↓
95
Financial Health ↑
43
Cash Quality ↑
25

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 63 quarters